1 |
Protocol for the development of the international population registry for aphasia after stroke (I-PRAISE)
|
|
|
|
In: Research outputs 2014 to 2021 (2022)
|
|
BASE
|
|
Show details
|
|
2 |
Protocol for the development of the international population registry for aphasia after stroke (I-PRAISE)
|
|
|
|
BASE
|
|
Show details
|
|
3 |
Utilising a systematic review-based approach to create a database of individual participant data for meta- and network meta-analyses: the RELEASE database of aphasia after stroke
|
|
|
|
BASE
|
|
Show details
|
|
4 |
Dosage, Intensity, and Frequency of Language Therapy for Aphasia: A Systematic Review-Based, Individual Participant Data Network Meta-Analysis
|
|
|
|
BASE
|
|
Show details
|
|
6 |
Communicating simply, but not too simply: Reporting of participants and speech and language interventions for aphasia after stroke
|
|
|
|
BASE
|
|
Show details
|
|
7 |
RELEASE: A protocol for a systematic review based, individual participant data, meta- and network meta-analysis, of complex speech-language therapy interventions for stroke-related aphasia
|
|
|
|
BASE
|
|
Show details
|
|
8 |
Tidier descriptions of speech and language therapy interventions for people with aphasia; consensus from the release collaboration
|
|
|
|
BASE
|
|
Show details
|
|
9 |
Aboriginal mitogenomes reveal 50,000 years of regionalism in Australia
|
|
|
|
BASE
|
|
Show details
|
|
10 |
Creating an international, multidisciplinary, aphasia dataset of individual patient data (IPD) for the REhabilitation and recovery of peopLE with Aphasia after StrokE (RELEASE) project
|
|
|
|
BASE
|
|
Show details
|
|
11 |
A continuum of admixture in the Western Hemisphere revealed by the African Diaspora genome ...
|
|
|
|
BASE
|
|
Show details
|
|
12 |
A continuum of admixture in the Western Hemisphere revealed by the African Diaspora genome
|
|
|
|
BASE
|
|
Show details
|
|
13 |
Contextual behavioural coaching: An evidence-based model for supporting behaviour change
|
|
|
|
In: 11 ; 2 ; 142 ; 154 (2016)
|
|
BASE
|
|
Show details
|
|
14 |
Studying the family diet: an investigation into association between diet, lifestyle and weight status in Malaysian families
|
|
|
|
BASE
|
|
Show details
|
|
15 |
A Benign Paroxysmal Positional Vertigo Specialty Clinic: A Model for Va Health Care
|
|
|
|
In: ETSU Faculty Works (2013)
|
|
BASE
|
|
Show details
|
|
16 |
Basal insulin and cardiovascular and other outcomes in dysglycemia.
|
|
Gerstein, H.C.; Bosch, J.; Dagenais, G.R.; Díaz, R.; Jung, H.; Maggioni, A.P.; Pogue, J.; Probstfield, J.; Ramachandran, A.; Riddle, M.C.; Rydén, L.E.; Yusuf, S.
|
|
In: New England Journal of Medicine, vol. 367, no. 4, pp. 319-328 (2012)
|
|
Abstract:
BACKGROUND: The provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events, but such a possibility has not been formally tested. METHODS: We randomly assigned 12,537 people (mean age, 63.5 years) with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes to receive insulin glargine (with a target fasting blood glucose level of ≤95 mg per deciliter [5.3 mmol per liter]) or standard care and to receive n-3 fatty acids or placebo with the use of a 2-by-2 factorial design. The results of the comparison between insulin glargine and standard care are reported here. The coprimary outcomes were nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and these events plus revascularization or hospitalization for heart failure. Microvascular outcomes, incident diabetes, hypoglycemia, weight, and cancers were also compared between groups. RESULTS: The median follow-up was 6.2 years (interquartile range, 5.8 to 6.7). Rates of incident cardiovascular outcomes were similar in the insulin-glargine and standard-care groups: 2.94 and 2.85 per 100 person-years, respectively, for the first coprimary outcome (hazard ratio, 1.02; 95% confidence interval [CI], 0.94 to 1.11; P=0.63) and 5.52 and 5.28 per 100 person-years, respectively, for the second coprimary outcome (hazard ratio, 1.04; 95% CI, 0.97 to 1.11; P=0.27). New diabetes was diagnosed approximately 3 months after therapy was stopped among 30% versus 35% of 1456 participants without baseline diabetes (odds ratio, 0.80; 95% CI, 0.64 to 1.00; P=0.05). Rates of severe hypoglycemia were 1.00 versus 0.31 per 100 person-years. Median weight increased by 1.6 kg in the insulin-glargine group and fell by 0.5 kg in the standard-care group. There was no significant difference in cancers (hazard ratio, 1.00; 95% CI, 0.88 to 1.13; P=0.97). CONCLUSIONS: When used to target normal fasting plasma glucose levels for more than 6 years, insulin glargine had a neutral effect on cardiovascular outcomes and cancers. Although it reduced new-onset diabetes, insulin glargine also increased hypoglycemia and modestly increased weight. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
|
|
Keyword:
Aged; Blood Glucose/analysis; Cardiovascular Diseases/epidemiology; Cardiovascular Diseases/etiology; Cholesterol/blood; Combination; Diabetes Mellitus; Double-Blind Method; Drug Therapy; Fasting; Fatty Acids; Female; Follow-Up Studies; Glucose Intolerance/complications; Glucose Intolerance/drug therapy; Hospitalization; Humans; Hypoglycemia/chemically induced; Hypoglycemic Agents/adverse effects; Hypoglycemic Agents/therapeutic use; Incidence; Insulin; Intention to Treat Analysis; Long-Acting/adverse effects; Long-Acting/therapeutic use; Male; Middle Aged; Omega-3/therapeutic use; Proportional Hazards Models; Triglycerides/blood; Type 2/complications; Type 2/drug therapy
|
|
URL: https://doi.org/10.1056/NEJMoa1203858 https://serval.unil.ch/notice/serval:BIB_24F963809D9F
|
|
BASE
|
|
Hide details
|
|
17 |
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
|
|
|
|
In: New England Journal of Medicine, vol. 367, no. 4, pp. 309-318 (2012)
|
|
BASE
|
|
Show details
|
|
18 |
Augmentation of bronchodilator responsiveness by leukotriene modifiers in Puerto Rican and Mexican children
|
|
|
|
BASE
|
|
Show details
|
|
19 |
40th EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004.
|
|
|
|
BASE
|
|
Show details
|
|
|
|